menu
    • menu

    Company profile for HTL Biotechnology

    NEW Drugs in Dev: 1
    HTL Biotech-PSE
    News
    EcoVadis Platinum Level Achieved in 2026

    13 Apr 2026

    // PRESS RELEASE

    HTL Biotechnology at PCHi 2026 in Hangzhou

    19 Mar 2026

    // PRESS RELEASE

    Gelmedix Wraps $13M Seed Funding, Reveals Initial Partnership

    17 Feb 2026

    // PR NEWSWIRE

    DATA COMPILATION
    #PharmaFlow

    HTL Biotechnology Biopolymer

    Contact Supplier

    Website

    CPhI Korea

    Exhibiting

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    speak-pharma/over-500-million-syringes-of-our-hyaluronic-acid-have-been-safely-used-worldwide

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    Key Products KEY PRODUCTS

    SERVICES

    Key Products KEY SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Related CompaniesRelated Companies

    About

    HTL is a biotechnology company specializing in the development and production of pharmaceutical-grade Hyaluronic Acid (Sodium Hyaluronate) and functional biopolymers such as PDRN and PN. HTL is the only producer exclusively manufacturing injectable-grade Hyaluronic Acid. Its premium biopolymers are used by healthcare companies to develop treatments in advanced therapeutic areas including ophthalmology, dermatology, medical aesthetics, and rheumatology. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    HTL BiotechnologyFrance Flag
    Country
    Country
    France
    Address
    Address
    7 Rue Alfred Kastler - ZI de l’Aumaillerie 35133 Javene
    Telephone
    Telephone
    +33 0299993737
    Client Email
    Email
    contact@htlbiotech.com
    Client Website
    Website
    https://htlbiotech.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/htl-biotechnology/
    youtube
    YouTube
    https://www.youtube.com/@htlbiotechnology
    Twitter
    Twitter
    https://x.com/HTL_Biotech
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    cphi-korea-png-33015.png

    CPhI Korea

    Exhibiting

    envelop Contact Supplier

    CPhI Korea

    Contact Supplier

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    INTERVIEW #SpeakPharma

    read-more
    read-more
    “Over 500 million syringes of our hyaluronic acid have been safely used worldwide”

    mic“Over 500 million syringes of our hyaluronic acid have been safely used worldwide”

    This week, SpeakPharma interviews Marie-Armelle Floc’h, Chief of Quality and Regulatory Affairs at HTL Biotechnology, a global leader in the development and the manufacturing of pharmaceutical-grade biopolymers headquartered in Javené, Brittany (France). Since 1992, HTL has pioneered the production of hyaluronic acid (HA) through proprietary biofermentation, achieving unmatched purity and consistency for applications in ophthalmology, dermatology and rheumatology. Floc’h highlights how HTL Biotechnology’s compelling portfolio of pharmaceutical-grade biopolymers is built on uncompromising quality standards. These standards have enabled the company to supply biopolymers for over 30 years without a single batch recall, firmly establishing its reputation for reliability and excellence. She also discusses the inauguration of HTL Biotechnology’s new sterile hyaluronic acid production unit — a major milestone that reinforces the company’s leadership in biopolymer manufacturing and enables the development of innovative formulations combining hyaluronic acid with thermo-sensitive active ingredients. This new capability opens the door to advanced biomedical applications where safety, stability and efficacy must be preserved without compromising the integrity of delicate molecules and which requires the highest quality standards. What distinguishes HTL Biotechnology’s biopolymer platforms in the market today? HTL Biotechnology has built its reputation on delivering pharmaceutical‑grade biopolymers (hyaluronic acid, polynucleotides and recombinant collagen) with unmatched purity and consistency. Since its founding in 1992, the company has focused on premium quality positioning. With more than 30 years of experience, HTL Biotechnology guarantees pharmaceutical-grade biopolymers of exceptional purity and exemplary consistency to our clients. We have had no batch recalls in 30 years, a record that underlines the rigor and reliability embedded in our processes. This was made possible by our fully-integrated site in France, where R&D laboratories, GMP manufacturing, quality control, and regulatory expertise are brought together under one roof. Such integration allows us to support our clients seamlessly throughout their product development journey, from early innovation through to global commercialization.Also, the inauguration of our new sterile hyaluronic acid production unit expands the possibilities for our HA to be used in advanced formulations with thermo-sensitive active ingredients, while upholding the uncompromising quality that defines HTL Biotechnology.Our operations are guided by internationally recognized standards, including ISO 13485 certification, which ensures the quality and safety required by medical device manufacturers worldwide.In addition, our Halal certification provides our customers with a significant advantage in accessing and expanding into markets where these requirements are essential for commercialization.Beyond certifications, our commitment to supporting global growth is reflected in the Drug Master Files we maintain across five continents, enabling our clients to accelerate product registration and bring innovative therapies to markets across the world more efficiently. By combining craftsmanship with pharmaceutical rigor, supported by state-of-the-art equipment and advanced bio-production methods, we ensure that every batch produced not only meets the strictest standards, but also delivers the reliability and consistency needed across the entire healthcare ecosystem. HIGHLIGHTS// Biopolymers with unmatched purity/record of no batch recalls/integrated facility in France/operations guided by global standards/new sterile HA unit for advanced formulations  Navigating the complex and evolving regulatory frameworks across global markets can be challenging for healthcare companies. Can you tell us more about how HTL Biotechnology supports its partners in this area? Regulatory support is part of our core premium services offer. We provide pharmaceutical regulatory support to ensure products meet the necessary compliance standards, so our partners can focus on their growth. Our dedicated regulatory professionals bring global and regional expertise, with a team specifically supporting customers in Asia. We offer personalized assistance adapted to their products and to the compliance standards of the target market. This includes personalized case-management support for regulatory file submissions with the concerned health authorities to minimize risks of refusal or delay, with the aim of achieving approval quickly and smoothly.Our offer for regulatory support continues beyond approval. We continuously monitor updates to regulations and provide post-commercialization support to our partners to help them manage any necessary regulatory updates.HIGHLIGHTS// Regulatory support offered as premium service/global and regional expertise/personalized case management for faster approvals/continuous regulatory support  How does HTL Biotechnology integrate sustainability and corporate responsibility into its operations? Sustainability is embedded in HTL Biotechnology’s strategic vision and day-to-day operations. In 2024, the company renewed its commitment to environmental responsibility by reinforcing its corporate social responsibility (CSR) roadmap. Tangible progress was made across multiple fronts: a 27 percent reduction in greenhouse gas emissions per kilogram of HA produced between 2021 and 2024, and a 34 percent reduction in water consumption per kilogram of HA since 2020. In 2024, we renewed the ISO 14001:2015 certification for its environmental management system, reflecting rigorous audit protocols and continual improvement cycles. All employees have been trained in the ISO 14001-certified environmental management system, and 78 percent of critical suppliers have signed HTL Biotechnology’s Responsible Purchasing Charter.These results reflect HTL Biotechnology’s structured and proactive approach to reducing its environmental footprint while maintaining the highest standards of quality and compliance.HIGHLIGHTS// Sustainability embedded in strategic vision/strong CSR roadmap with measurable progress/reduction in greenhouse gas emissions/responsible sourcing 

    Impressions: 3585

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/over-500-million-syringes-of-our-hyaluronic-acid-have-been-safely-used-worldwide

    PharmaCompass
    04 Nov 2025
    Share info Share

    CORPORATE CONTENT #SupplierSpotlight

    Product List 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/htl-biotechnology-party-content-62936.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Corporate Presentation

    read-more

      https://www.pharmacompass.com/pdf/party/content/htl-biotechnology-party-content-47305.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    GMP Certificate 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/htl-biotechnology-party-content-19770.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Premium Quality Hyaluronic Acid

    read-more

      https://www.pharmacompass.com/pdf/party/content/htl-biotechnology-party-content-75810.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Premium Quality PDRN

    read-more

      https://www.pharmacompass.com/pdf/party/content/htl-biotechnology-party-content-29632.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Premium Quality Sodium DNA

    read-more

      https://www.pharmacompass.com/pdf/party/content/htl-biotechnology-party-content-38696.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    New Bioproduction Unit for Pharmaceutical Grade Biopolymers

    read-more

      https://www.pharmacompass.com/pdf/party/content/htl-biotechnology-party-content-10491.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    NEWS #PharmaBuzz

    read-more
    read-more
    EcoVadis Platinum Level Achieved in 2026
    EcoVadis Platinum Level Achieved in 2026

    13 Apr 2026

    // PRESS RELEASE

    https://htlbiotech.com/news/ecovadis-platinum-level-achieved-in-2026/

    PRESS RELEASE
    13 Apr 2026
    Share Share
    HTL Biotechnology at PCHi 2026 in Hangzhou
    HTL Biotechnology at PCHi 2026 in Hangzhou

    19 Mar 2026

    // PRESS RELEASE

    https://htlbiotech.com/news/htl-biotechnology-at-pchi-2026-in-hangzhou/

    PRESS RELEASE
    19 Mar 2026
    Share Share
    Gelmedix Wraps $13M Seed Funding, Reveals Initial Partnership
    Gelmedix Wraps $13M Seed Funding, Reveals Initial Partnership

    17 Feb 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/gelmedix-completes-13-million-seed-financing-and-announces-first-partnership-302689235.html

    PR NEWSWIRE
    17 Feb 2026
    Share Share
    HTL Biotech at IMCAS'26: future of regenerative medicine
    HTL Biotech at IMCAS'26: future of regenerative medicine

    01 Feb 2026

    // PRESS RELEASE

    https://htlbiotech.com/news/htl-biotechnology-at-imcas-2026-advancing-the-future-of-regenerative-medicine/

    PRESS RELEASE
    01 Feb 2026
    Share Share
    HTL Biotechnology joins the Choiseul Conquérants 2025 ranking
    HTL Biotechnology joins the Choiseul Conquérants 2025 ranking

    12 Dec 2025

    // PRESS RELEASE

    https://htlbiotech.com/news/htl-biotechnology-joins-the-choiseul-conquerants-2025-ranking/

    PRESS RELEASE
    12 Dec 2025
    Share Share
    HTL Bio Inside Webinar: Success that boost our visibility in Asia
    HTL Bio Inside Webinar: Success that boost our visibility in Asia

    29 Oct 2025

    // PRESS RELEASE

    https://htlbiotech.com/news/htl-inside-webinar-a-success-that-boosts-our-visibility-in-asia/

    PRESS RELEASE
    29 Oct 2025
    Share Share

    KEY PRODUCTS

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Sponsored Ads.
    full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view

    Services

    Discover the service capabilities from this company

    API Manufacturing

    Discover their expertise for : API Manufacturing

    KEY SERVICES

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    HTL Biotechnology Biopolymer full-view

    TOP RANKED SUPPLIER FOR:

    Functionalized Biopolymers Services
    full-view

    Inspections and registrations

    Check the inspections & registration from this company
    HTL Biotechnology Biopolymer

    ABOUT THIS PAGE

    Contact HTL Biotechnology and get a quotation

    HTL Biotechnology is a supplier offers 5 products (APIs, Excipients or Intermediates).

    Find Sodium Hyaluronate bulk with DMF, CEP, JDMF offered by HTL Biotechnology

    Find Sodium Hyaluronate bulk with DMF, CEP offered by HTL Biotechnology

    Find Sodium Hyaluronate bulk offered by HTL Biotechnology

    Find Hyaluronic Acid bulk offered by HTL Biotechnology

    Find Sodium DNA bulk offered by HTL Biotechnology

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search